- Home
- DLPN vs BCLI Comparison
DLPN vs BCLI Comparison
Compare DLPN & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLPN
- BCLI
- Stock Information
- Founded
- DLPN N/A
- BCLI 2000
- Country
- DLPN United States
- BCLI United States
- Employees
- DLPN N/A
- BCLI N/A
- Industry
- DLPN Other Consumer Services
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DLPN Consumer Discretionary
- BCLI Health Care
- Exchange
- DLPN Nasdaq
- BCLI Nasdaq
- Market Cap
- DLPN 12.9M
- BCLI 13.5M
- IPO Year
- DLPN N/A
- BCLI N/A
- Fundamental
- Price
- DLPN $1.04
- BCLI $1.89
- Analyst Decision
- DLPN Strong Buy
- BCLI Strong Buy
- Analyst Count
- DLPN 1
- BCLI 1
- Target Price
- DLPN $5.00
- BCLI $30.00
- AVG Volume (30 Days)
- DLPN 50.1K
- BCLI 109.6K
- Earning Date
- DLPN 11-14-2024
- BCLI 11-14-2024
- Dividend Yield
- DLPN N/A
- BCLI N/A
- EPS Growth
- DLPN N/A
- BCLI N/A
- EPS
- DLPN N/A
- BCLI N/A
- Revenue
- DLPN $51,389,626.00
- BCLI N/A
- Revenue This Year
- DLPN $21.74
- BCLI N/A
- Revenue Next Year
- DLPN $7.26
- BCLI N/A
- P/E Ratio
- DLPN N/A
- BCLI N/A
- Revenue Growth
- DLPN 21.66
- BCLI N/A
- 52 Week Low
- DLPN $0.90
- BCLI $1.05
- 52 Week High
- DLPN $3.28
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- DLPN 45.58
- BCLI 44.80
- Support Level
- DLPN $0.98
- BCLI $1.90
- Resistance Level
- DLPN $1.39
- BCLI $2.17
- Average True Range (ATR)
- DLPN 0.10
- BCLI 0.18
- MACD
- DLPN -0.01
- BCLI -0.05
- Stochastic Oscillator
- DLPN 15.27
- BCLI 4.76
About DLPN Dolphin Entertainment Inc.
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.